Author

Deanna C Hissim

Observed names: D. Hissim, Deanna Hissim

Institution: Wake Forest University

Observed institutions: Atrium Health Wake Forest Baptist, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University Health Sciences, Wake Forest University

OpenAlex ID: A5046967692

Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.

2022 · Jian Li Campian, Omar H. Butt, et al. · Journal of Clinical Oncology · 6

278O Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295

2022 · J.L. Campian, O. Butt, et al. · Annals of Oncology · 3

Ctim-10. a Phase Ii Study of Retifanlimab (pd-1 Inhibitor) in Combination With Bevacizumab and Hypofractionated Radiotherapy for Recurrent Glioblastoma: Nct03532295

2022 · Omar Butt, Jiayi Huang, et al. · Neuro-Oncology · 2

Ctim-23. a Phase Ii Study of Retifanlimab (pd-1 Inhibitor) and Epacadostat (ido1 Inhibitor) in Combination With Bevacizumab and Hypofractionated Radiotherapy for Recurrent Glioblastoma: Nct03532295

2024 · Abeer Butt, Jingqin Luo, et al. · Neuro-Oncology

Works count: 4

Citation count: 11

H-index: 2

I10-index: